The prognostic significance of peroxisome proliferator-activated receptor β expression in the vascular endothelial cells of colorectal cancer
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Currently, little is known regarding the role of peroxisome proliferator-activated receptor-β (PPAR β) in the vascular endothelial cells (VECs) of colorectal cancers (CRCs). The aim of this study was to investigate the relationship of PPAR β expression in the VECs of CRCs in terms of the prognosis and clinicopathological features of CRC patients.
The expression and localization of PPAR β in the primary cancers and the matched normal mucosal samples of 141 Swedish CRC patients were analyzed in terms of its correlation with clinicopathological features and the expression of angiogenesis-related genes. This study also included 92 Chinese CRC patients.
PPAR β was predominantly localized in the cytoplasm and was significantly downregulated in the VECs of CRC compared to that of the normal mucosa. The low expression levels of PPAR β in the VECs of CRC were statistically correlated with enhanced differentiation, early staging and favorable overall survival and were associated with the increased expression of VEGF and D2-40. The patients exhibiting elevated expression of PPAR β in CRC cells but reduced expression in VECs exhibited more favorable survival compared with the other patients, whereas the patients with reduced expression of PPAR β in CRC cells but increased expression in VECs exhibited less favorable prognosis.
PPAR β might play a tumor suppressor role in CRC cells in contrast to a tumor promoter role in the VECs of CRCs.
- Molnar F, Matilainen M, Carlberg C. Structural determinants of the agonist-independent association of human peroxisome proliferator-activated receptors with coactivators. J Biol Chem. 2005;280:26543–56. CrossRef
- Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, Orahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W. International union of pharmacology. LXI peroxisome proliferator-activated receptors. Pharmacol Rev. 2006;58:726–41. CrossRef
- Desvergne B, Michalik L, Wahli W. Transcriptional regulation of metabolism. Physiol Rev. 2006;86:465–514. CrossRef
- Kostadinova R, Wahli W, Michalik L. PPARs in diseases: control mechanisms of inflammation. Curr Med Chem. 2005;12:2995–3009. CrossRef
- Kilgore KS, Billin AN. PPARβ/δ ligands as modulators of the inflammatory response. Curr Opin Investig Drugs. 2008;9:463–9.
- Kim DJ, Bility MT, Billin AN, Willson TM, Gonzalez FJ, Peters JM. PPAR beta/delta selectively induces differentiation and inhibits cell proliferation. Cell Death Differ. 2006;13:53–60. CrossRef
- Nadra K, Anghel SI, Joye E, Tan NS, Basu-Modak S, Trono D, Wahli W, Desvergne B. Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. Mol Cell Biol. 2006;26:3266–81. CrossRef
- Varnat F, Heggeler BB, Grisel P, Boucard N, Corthesy-Theulaz I, Wahli W, Desvergne B. PPAR beta/delta regulates paneth cell differentiation via controlling the hedgehog signaling pathway. Gastroenterology. 2006;131:538–53. CrossRef
- Brusselbach SM, Komhoff M, Rieck M, Meissner W, Kaddatz K, Adamkiewicz J, Keil B, Klose KJ, Moll R, Burdick AD, Peters JM, Muller R. Deregulation of tumor angiogenesis and blockade of tumor growth in PPAR beta-deficient mice. EMBO J. 2007;26:3686–98. CrossRef
- Wang DZ, Wang HB, Guo Y, Ning W, Katkuri S, Wahli W, Desvergne B, Dey SK, Dubois RN. Crosstalk between peroxisome proliferator-activated receptor-delta and VEGF stimulates cancer progression. PNAS. 2006;103:19069–74. CrossRef
- Rohrl C, Kaindl U, Koneczny I, Hudec X, Baron DM, Konig JS, Marian B. Peroxisome-proliferator-activated receptors γ and β/δ mediate vascular endothelial growth factor production in colorectal tumor cells. J Cancer Res Clin Oncol. 2011;137:29–39. CrossRef
- Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis. Nat Med. 2004;10:481–3. CrossRef
- He TC, Chan TA, Vogelstein B, Kinzler KW. PPAR δ is an APC regulated target of nonsteroidal anti-inflammatory drugs. Cell. 1999;99:335–45. CrossRef
- Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth. Nat Med. 2004;10:245–7. CrossRef
- Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R, Evans RM. Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA. 2002;99:303–8. CrossRef
- Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B, Das SK, Dey SK, DuBois RN. Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ. Cancer Cell. 2004;6:285–95. CrossRef
- Yang L, Zhang H, Zhou ZG, Yan H, Adell G, Sun XF. Biological function and prognostic significance of peroxisome proliferator-activated receptor δ in rectal cancer. Clin Cancer Res. 2011;17:3760–70. CrossRef
- Yang L, Olsson B, Pfeifer D, Jonsson JI, Zhou ZG, Jiang X, Fredriksson BA, Zhang H, Sun XF. Knockdown of peroxisome proliferator-activated receptor-δ induces less differentiation and enhances cell fibronectin adhesion of colon cancer cells. Oncogene. 2010;29:516–26. CrossRef
- Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438:932–6. CrossRef
- Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–64. CrossRef
- Abdoll A, Schwager C, Kleeff J, Esposito I, Domhan S, Peschke P, Hauser K, Hahnfeldt P, Hlatky L, Debus J, Peters JM, Friess H, Folkman J, Huber PE. Transcriptional network governing the angiogenic switch in human pancreatic cancer. PNAS. 2007;104:12890–5. CrossRef
- Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, Tanabe T, Warner TD, Bishop-Bailey D. Activation of PPAR beta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol. 2007;27:63–9. CrossRef
- Gao J, Arbman G, Rearden A, Sun XF. Stromal staining for PINCH is an independent prognostic indicator in colorectal cancer. Neoplasia. 2004;6:796–801. CrossRef
- Gao J, Knutsen A, Arbman G, Carstensen J, Franlund B, Sun XF. Clinical and biological significance of angiogenesis and lymphangiogenesis in colorectal cancer. Dig Liver Dis. 2009;41:116–22. CrossRef
- Muller R, Rieck M, Brusselbach SM. Regulation of cell proliferation and differentiation by PPAR β. PPAR Res. 2008. doi:10.1155/2008/614852.
- Hollingshead HE, Morimura K, Adachi M, Kennett MJ, Billin AN, Willson TM, Gonzalez FJ, Peters JM. PPAR beta/delta protects against experimental colitis through a ligand-independent mechanism. Dig Dis Sci. 2007;52:2912–9. CrossRef
- Sun XF, Zhang H. Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas. BMC Mol Cancer. 2006;5:43. CrossRef
- Glienke J, Schmitt AO, Pilarsky C, Hinzmann B, Weiss B, Rosenthal A, Thierauch KH. Differential gene expression by endothelial cells in distinct angiogenic states. Eur J Biochem. 2000;267:2820–30. CrossRef
- Zhang ZY, Tian YF, Wang YY, Zhang LJ, Zhao ZR, Sun XF. PINCH mRNA overexpression in colorectal carcinomas correlated with VEGF and FAS mRNA expression. Anticancer Res. 2011;31:4127–33.
- Romero S, Szafranska J, Cabrera E, Gonzalez A, Peiro A, Llauger J, Ortega L, Bague S, Canet B, Espinosa I, Prat J. Role of tumor-associated macrophages and angiogenesis in desmoids-type fibromatosis. Virchows Arc. 2012;461:117–22.
- Moon HS, Liu X, Nagel JM, Chamberland JP, Diakopoulos KN, Brinkoetter MT, Hatziapostolou M, Wu Y, Robson SC, Iliopoulos D, Mantzoros CS. Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice. Gut. 2013;62:561–71.
- Jakob C, Aust DE, Liebscher B, Baretton GB, Datta K, Muders MH. Lymphangiogenesis in regional lymph nodes is an independent prognostic marker in rectal cancer patients after neoadjuvant treatment. PLoS ONE. 2011;6:327402.
- Cimpean AM, Poenaru Sava M, Raica M, Ribatti D. Preliminary evidence of the presence of lymphatic vessels immunoreactive for D2-40 and Prox-1 in human pterygium. Oncol Rep. 2011;26:1111–3.
- Takayama O, Yamamoto H, Damdinsuren B, Sugita Y, Ngan CY, Xu X, Tsujino T, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Monden M. Expression of PPAR delta in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. Br J Cancer. 2006;95:889–95. CrossRef
- Yoshinaga M, Kitamura Y, Chaen T, Yamashita S, Tsuruta S, Hisano T, Ikeda Y, Sakai H, Nakamura K, Takayanagi R, Muto Y. The simultaneous expression of peroxisome proliferator-activated receptor delta and cyclooxygenase-2 may enhance angiogenesis and tumor venous invasion in tissues of colorectal cancer. Dig Dis Sci. 2009;54:1108–14. CrossRef
- Girroir EE, Hollingshead HE, He P, Zhu B, Perdew GH, Peters JM. Quantitative expression patterns of peroxisome proliferator-activated receptor-β (PPAR β) protein in mice. BBRC. 2008;371:456–61.
- The prognostic significance of peroxisome proliferator-activated receptor β expression in the vascular endothelial cells of colorectal cancer
Journal of Gastroenterology
Volume 49, Issue 3 , pp 436-445
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Peroxisome proliferator-activated receptor-β
- Colorectal cancer
- Vascular endothelial cells
- Industry Sectors
- Author Affiliations
- 1. Institute of Digestive Surgery and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China
- 2. Department of Surgery, Vrinnevi Hospital, Norrköping, Sweden
- 3. Laboratory of Stem Cell Biology and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China
- 4. Department of Oncology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China
- 5. Division of Oncology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Country Council of Östergötland, Linköping, Sweden